In this video, Meryl D. Colton, MD, University of Colorado, Denver, CO, briefly discusses the role of measurable residual disease (MRD) in treatment decisions and minimizing late toxicities in patients with non-Hodgkin lymphoma (NHL). Dr Colton highlights the importance of using MRD in prognosis and when detecting early refractoriness or relapse, as well as its role in the future use of CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
